Peripheral Artery Disease

Peripheral artery disease (PAD) involves atherosclerosis mainly in the extremities, especially in the legs and feet that lead to ischemia. Untreated, PAD can progress to critical limb ischemia (CLI), also called chronic limb-threatening ischemia (CLTI), which will lead to foot or leg amputation. The mortality rate for these CLI amputees is 70% within three years. There is currently an epidemic of PAD and CLI in the U.S. The majority of patients are defined by health disparities concentrated in the Black, Latino, Native American populations in both rural and low-income urban areas. A large number of PAD patients have other comorbities, with diabetes being one a primary issue.

New guidelines help interventional cardiologists manage chronic venous disease
"These recommendations will help ensure that patient care remains both consistent and personalized," SCAI President Srihari S. Naidu, MD, explained.
Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
New-look peripheral stent with expandable spikes receives FDA’s de novo classification
California-based Reflow Medical gained the approval after submitting data from the DEEPER REVEAL clinical trial. The device was associated with a high success rate and improved outcomes in CLTI patients.
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

PAD specialists announce new FDA clearance for image-guided atherectomy system

The solution is now cleared as a treatment option for in-stent restenosis in the lower extremity arteries.

New survey examines the biggest issues impacting care for CAD, PAD patients

Physicians, industry leaders—and, yes, patients themselves—provided an updated look at the state of vascular care in 2021.

Hispanic PAD patients often face longer hospitalizations, higher costs

Hispanic adults with peripheral artery disease tend to seek care through the emergency department—and they are paying the price.

‘Saving lives and saving limbs’: New study of real-world CMS patients highlights the benefits of IVUS

The Smith Center for Outcomes Research in Cardiology examined real-world data from more than 700,000 CMS patients. The group's findings were presented during TCT 2021.

PAD patients more likely to die from COVID-19

The mortality rate for COVID-19 patients was nearly twice as high if they had a history of peripheral artery disease, researchers found.

Many PAD patients are missing out on vital risk assessments

The findings, based on Medicare data, were presented at VIVA21 in Las Vegas.

First patient treated with CSI’s new peripheral support catheter

A vascular surgeon in Nashville performed the procedure, praising the device's "balance of support and flexibility."

Rivaroxaban limits adverse limb and cardiovascular events in surgically treated PAD patients

Rivaroxaban was associated with more bleeding than a placebo, researchers observed, but the overall incidence of such events was still low.

Peripheral Artery Disease

New guidelines help interventional cardiologists manage chronic venous disease

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

New-look peripheral stent with expandable spikes receives FDA’s de novo classification

Late-breaking cardiovascular drug trials took center stage at ACC.25

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes